Urinary Biomarkers in Monitoring the Progression and Treatment of Autosomal Dominant Polycystic Kidney Disease—The Promised Land?
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease, and it leads to end-stage renal disease (ESRD). The clinical manifestations of ADPKD are variable, with extreme differences observable in its progression, even among members of the same family with the sa...
Main Authors: | Camelia Pana, Alina Mihaela Stanigut, Bogdan Cimpineanu, Andreea Alexandru, Camer Salim, Alina Doina Nicoara, Periha Resit, Liliana Ana Tuta |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-05-01
|
Series: | Medicina |
Subjects: | |
Online Access: | https://www.mdpi.com/1648-9144/59/5/915 |
Similar Items
-
Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
by: Raina R, et al.
Published: (2022-09-01) -
Predicting autosomal dominant polycystic kidney disease progression: review of promising Serum and urine biomarkers
by: Iva Sorić Hosman, et al.
Published: (2023-11-01) -
Cyst Fraction as a Biomarker in Autosomal Dominant Polycystic Kidney Disease
by: Larina A. Karner, et al.
Published: (2022-12-01) -
Gallbladder cancer concomitant with autosomal dominant polycystic kidney disease: A case report
by: Hisashi Murakami, et al.
Published: (2022-12-01) -
Pleural Effusions on MRI in Autosomal Dominant Polycystic Kidney Disease
by: Jin Liu, et al.
Published: (2023-01-01)